Developmental and Behavioral Comorbidities of Asthma in Children

Blackman, James A.; Gurka, Matthew J.

doi:10.1097/01.dbp.0000267557.80834.e5

Cited by 197 publications

(190 citation statements)

References 32 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Indeed, although children with asthma and their families have a higher rate of psychiatric conditions, particularly depression and anxiety, than unaffected ones [28,29], such conditions are often underrepresented in drug trials due to concerns about adherence [12]. Yet oral montelukast is particularly attractive to improve adherence in these patients, possibly explaining the notable proportion of children and parents with mood and behaviour disorders in our cohort.…”

Section: Discussionmentioning

confidence: 94%

Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice

et al. 2017

View full text Add to dashboard Cite

@ERSpublicationsThe incidence of children on montelukast with drug cessation due to neuropsychiatric adverse events was >10% http://ow.ly/nCGG30bgjpd ABSTRACT Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration black box warning. The objective of this study was to determine the incidence of neuropsychiatric ADRs leading to discontinuation of montelukast in asthmatic children.We conducted a retrospective cohort study in children aged 1-17 years initiated on montelukast. In a nested cohort study, children initiated on montelukast as monotherapy or adjunct therapy to inhaled corticosteroids (ICS) were matched to those initiated on ICS monotherapy. A non-leading parental interview served to ascertain the occurrence of any ADRs with any asthma medication, and circumstances related to, and evolution of, the event.Out of the 106 participants who initiated montelukast, most were male (58%), Caucasian (62%) with a median (interquartile range) age of 5 (3-8) years. The incidence (95% CI) of drug cessation due to neuropsychiatric ADRs was 16 (10-26)%, mostly occurring within 2 weeks. Most frequent ADRs were irritability, aggressiveness and sleep disturbances. The relative risk of neuropsychiatric ADRs associated with montelukast versus ICS was 12 (2-90).In the real-life setting, asthmatic children initiated on montelukast experienced a notable risk of neuropsychiatric ADRs leading to drug cessation, that is significantly higher than that associated with ICS.

show abstract

Section: Discussionmentioning

confidence: 94%

Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…33,34 Intriguingly, a recent genome-wide association study has implicated PTPRD as a locus for RLS. 35 Moreover, genetic variants of PTPRD associate with bronchial asthma, 36 which is reported to occur at higher rates in children with ADHD, 37 and RLS patients have been shown to have increased use of asthma medications. 38 Studies of the PTPRD gene in mice show high expression in the hippocampus, the only brain region reported to be enlarged in ADHD, 39 along with involvement in spatial learning, long-term potentiation and axonal guidance of motor neurons.…”

Section: Resultsmentioning

confidence: 99%

Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes

et al. 2009

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a common and highly heritable disorder, but specific genetic factors underlying risk remain elusive. To assess the role of structural variation in ADHD, we identified 222 inherited copy number variations (CNVs) within 335 ADHD patients and their parents that were not detected in 2026 unrelated healthy individuals. Although no excess CNVs, either deletions or duplications, were found in the ADHD cohort relative to controls, the inherited rare CNV-associated gene set was significantly enriched for genes reported as candidates in studies of autism, schizophrenia and Tourette syndrome, including A2BP1, AUTS2, CNTNAP2 and IMMP2L. The ADHD CNV gene set was also significantly enriched for genes known to be important for psychological and neurological functions, including learning, behavior, synaptic transmission and central nervous system development. Four independent deletions were located within the protein tyrosine phosphatase gene, PTPRD, recently implicated as a candidate gene for restless legs syndrome, which frequently presents with ADHD. A deletion within the glutamate receptor gene, GRM5, was found in an affected parent and all three affected offspring whose ADHD phenotypes closely resembled those of the GRM5 null mouse. Together, these results suggest that rare inherited structural variations play an important role in ADHD development and indicate a set of putative candidate genes for further study in the etiology of ADHD.

show abstract

“…Another psychological condition, attention deficit hyperactivity disorder has been proposed as a comorbidity possibly influencing asthma. However, controversial data have been published on their relationship [132][133][134][135]. Fasmer et al recently assessed how frequently drugs used to treat asthma and attention deficit hyperactivity disorder are prescribed to the same patients in looking at data from the Norwegian Prescription Database for 2006 [136].…”

Section: Psychopathologiesmentioning

confidence: 99%